Reports on Anti-VEGF Agents Explode at ARVO.

The article offers information on how anti-vascular endothelial growth factor (VEGF) therapy treat diabetes and vein occlusion as demonstrated at the Association for Research in Vision and Ophthalmology (ARVO) meeting in the U.S. Researchers from London notes that three-strikes method of administering anti-VEGF injections in AMD patients is cost-effective and practical. Researchers from Honolulu states that switching patients from anti-VEGF therapy to ranibizumab injections improve outcomes.